35.65
price up icon0.17%   0.06
 
loading
Schlusskurs vom Vortag:
$35.59
Offen:
$35.785
24-Stunden-Volumen:
2.34M
Relative Volume:
0.60
Marktkapitalisierung:
$15.02B
Einnahmen:
$2.26B
Nettoeinkommen (Verlust:
$1.09B
KGV:
15.21
EPS:
2.3431
Netto-Cashflow:
$2.70B
1W Leistung:
-1.63%
1M Leistung:
+2.27%
6M Leistung:
+17.66%
1J Leistung:
+26.69%
1-Tages-Spanne:
Value
$35.51
$35.92
1-Wochen-Bereich:
Value
$35.24
$36.89
52-Wochen-Spanne:
Value
$24.05
$36.89

Royalty Pharma Plc Stock (RPRX) Company Profile

Name
Firmenname
Royalty Pharma Plc
Name
Telefon
(212) 883-0200
Name
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Name
Mitarbeiter
99
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
RPRX's Discussions on Twitter

Vergleichen Sie RPRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RPRX
Royalty Pharma Plc
35.65 15.27B 2.26B 1.09B 2.70B 2.3431
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-16 Eingeleitet Morgan Stanley Overweight
2024-06-03 Herabstufung UBS Buy → Neutral
2022-06-14 Fortgesetzt UBS Buy
2022-05-13 Eingeleitet Scotiabank Sector Outperform
2022-04-27 Eingeleitet Goldman Buy
2022-04-14 Hochstufung JP Morgan Neutral → Overweight
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2021-10-29 Hochstufung Citigroup Neutral → Buy
2021-07-30 Eingeleitet Tigress Financial Buy
2020-11-09 Hochstufung UBS Neutral → Buy
2020-07-14 Eingeleitet Evercore ISI In-line
2020-07-13 Eingeleitet BofA Securities Buy
2020-07-13 Eingeleitet Citigroup Neutral
2020-07-13 Eingeleitet Cowen Outperform
2020-07-13 Eingeleitet Goldman Neutral
2020-07-13 Eingeleitet JP Morgan Neutral
2020-07-13 Eingeleitet Morgan Stanley Equal-Weight
2020-07-13 Eingeleitet SunTrust Buy
2020-07-13 Eingeleitet UBS Neutral
Alle ansehen

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

pulisher
05:04 AM

Royalty Pharma (RPRX) PT Raised to $42 at Citi - StreetInsider

05:04 AM
pulisher
03:53 AM

What drives Royalty Pharma plc stock priceFree Technical Analysis Support - jammulinksnews.com

03:53 AM
pulisher
03:16 AM

What analysts say about Royalty Pharma plc stockOver 200% growth - jammulinksnews.com

03:16 AM
pulisher
Jul 21, 2025

C WorldWide Group Holding A S Acquires New Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 21, 2025
pulisher
Jul 21, 2025

Los Angeles Capital Management LLC Grows Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 21, 2025
pulisher
Jul 20, 2025

Royalty Pharma plc Stock Analysis and ForecastConsistent triple returns - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Royalty Pharma PLC (NASDAQ:RPRX) Stake Raised by Victory Capital Management Inc. - MarketBeat

Jul 20, 2025
pulisher
Jul 20, 2025

Is Royalty Pharma plc a good long term investmentFree Trend-Following Techniques - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Edgestream Partners L.P. Invests $659,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 20, 2025
pulisher
Jul 20, 2025

Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighTime to Buy? - MarketBeat

Jul 20, 2025
pulisher
Jul 19, 2025

Cullen Frost Bankers Inc. Has $7.72 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 19, 2025
pulisher
Jul 19, 2025

Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Share - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Ordinary Share - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Royalty Pharma PLC Announces Quarterly Dividend of $0.22 (NASDAQ:RPRX) - MarketBeat

Jul 18, 2025
pulisher
Jul 18, 2025

Royalty Pharma Declares Third Quarter 2025 Dividend - The Globe and Mail

Jul 18, 2025
pulisher
Jul 18, 2025

Royalty Pharma announces $0.22 per share dividend for Q3 2025 - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Royalty Pharma plc (RPRX) Declares $0.22 Quarterly Dividend; 2.5% Yield - StreetInsider

Jul 18, 2025
pulisher
Jul 18, 2025

Royalty Pharma Announces Q3 2025 Dividend of $0.22 per Share - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 18, 2025

Bryn Mawr Capital Management LLC Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 18, 2025
pulisher
Jul 18, 2025

Is Royalty Pharma plc stock a good hedge against inflationHigh Potential Safe Trades - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Royalty Pharma adds two independent directors to board By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors - The Manila Times

Jul 17, 2025
pulisher
Jul 17, 2025

Royalty Pharma adds two independent directors to board - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% - Quiver Quantitative

Jul 17, 2025
pulisher
Jul 17, 2025

Royalty Pharma Appoints Denali CMO and Warburg Pincus Veteran to Board Following Major Acquisition - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

Strata Wealth Advisors LLC Invests $387,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 17, 2025
pulisher
Jul 17, 2025

Cerity Partners LLC Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 17, 2025
pulisher
Jul 17, 2025

Bank of New York Mellon Corp Has $45.53 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 17, 2025
pulisher
Jul 16, 2025

Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times

Jul 16, 2025
pulisher
Jul 16, 2025

Royalty Pharma Q2 2025 Earnings Call: Key Details for August 6 Pre-Market Release - Stock Titan

Jul 16, 2025
pulisher
Jul 15, 2025

Why Royalty Pharma plc stock attracts strong analyst attentionDaily Swing Candidates - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Royalty Pharma plc stock performs during market volatilityMarket Timing Advice - beatles.ru

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Royalty Pharma plc stock price move sharplyFree Trading Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

M&T Bank Corp Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Fiera Capital Announces the Termination of imaxx Canadian Fixed Pay Fund and of imaxx Short Term Bond Fund - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

Bank of New York Mellon Corp Has $45.53 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Rehmann Capital Advisory Group Purchases Shares of 17,649 Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 14, 2025
pulisher
Jul 13, 2025

D.A. Davidson & CO. Trims Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighTime to Buy? - MarketBeat

Jul 13, 2025
pulisher
Jul 12, 2025

Teacher Retirement System of Texas Sells 12,028 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 12, 2025
pulisher
Jul 11, 2025

Royalty Pharma stock hits 52-week high at 36.44 USD By Investing.com - Investing.com South Africa

Jul 11, 2025

Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.69
price down icon 0.87%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Kapitalisierung:     |  Volumen (24h):